Compare · ADMA vs RVMD
ADMA vs RVMD
Side-by-side comparison of ADMA Biologics Inc (ADMA) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADMA and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $39.58B, about 19.6x ADMA ($2.02B).
- RVMD has been more active in the news (15 items in the past 4 weeks vs 1 for ADMA).
- RVMD has more recent analyst coverage (25 ratings vs 10 for ADMA).
- Company
- ADMA Biologics Inc
- Revolution Medicines Inc.
- Price
- $8.72-1.13%
- $186.14+3.91%
- Market cap
- $2.02B
- $39.58B
- 1M return
- +1.28%
- -
- 1Y return
- -47.94%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 1
- 15
- Recent ratings
- 10
- 25
ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest ADMA
- CFO and Treasurer Kohler Terry was granted 85,130 shares, increasing direct ownership by 147% to 143,149 units (SEC Form 4)
- Raymond James resumed coverage on ADMA Biologics with a new price target
- ADMA Biologics Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Grossman Jerrold B bought $50,624 worth of shares (6,400 units at $7.91), increasing direct ownership by 1% to 520,284 units (SEC Form 4)
- Director Grossman Jerrold B bought $100,125 worth of shares (12,500 units at $8.01), increasing direct ownership by 2% to 513,884 units (SEC Form 4)
- Director Grossman Jerrold B bought $100,125 worth of shares (12,500 units at $8.01), increasing direct ownership by 3% to 501,384 units (SEC Form 4)
- SEC Form 10-Q filed by ADMA Biologics Inc
- ADMA Biologics Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
- ADMA Biologics Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest RVMD
- European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
- Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Patel Sushil exercised 2,955 shares at a strike of $37.54 and sold $1,048,967 worth of shares (5,580 units at $187.99) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 21,656 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 20,000 shares at a strike of $18.56 and sold $3,366,604 worth of shares (20,000 units at $168.33) as part of a pre-agreed trading plan (SEC Form 4)
- Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Kim Lorence H. was granted 1,191 shares, increasing direct ownership by 2% to 74,281 units (SEC Form 4)
- Director Borisy Alexis was granted 1,191 shares, increasing direct ownership by 0.05% to 2,340,075 units (SEC Form 4)
- Director Anderson Elizabeth M was granted 1,191 shares, increasing direct ownership by 14% to 9,406 units (SEC Form 4)
- Director Horning Sandra was granted 1,191 shares, increasing direct ownership by 1% to 97,765 units (SEC Form 4)
- Director Clyburn Frank was granted 1,191 shares, increasing direct ownership by 12% to 10,929 units (SEC Form 4)